<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937077</url>
  </required_header>
  <id_info>
    <org_study_id>2013/2371</org_study_id>
    <nct_id>NCT02937077</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation in Cryptogenic Stroke and TIA</brief_title>
  <acronym>NOR-FIB</acronym>
  <official_title>The Nordic Atrial Fibrillation and Stroke Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      Different studies with real-life data and randomized controlled trials have shown a detection
      rate of paroxysmal atrial fibrillation (AF) of 10-20% in patients with cryptogenic stroke
      using insertable continuous cardiac monitoring for 6 months. More studies are needed,
      however, to identify factors which can be used to select the patients where the possibility
      of detecting AF with prolonged rhythm monitoring is highest, to evaluate the best duration of
      rhythm monitoring, to determine the optimal deﬁnition of short-term AF that warrants
      intervention and to evaluate whether intervention results in improved clinical outcomes.

      Methods: The NOR-FIB study is a multi-centre prospective observational trial, designed to
      evaluate detection of AF in cryptogenic stroke and transient ischemic attack (TIA). Patients
      admitted with cryptogenic stroke or TIA in stroke units in the Nordic countries, aged 18-80
      years are included and have the Reveal LINQ® Insertable cardiac monitor system implanted for
      12 months for the purpose of AF detection. Biomarkers that may identify patients, who could
      derive the most clinical benefit from the detection of AF by prolonged monitoring, are being
      studied.

      Conclusion: This NOR-FIB study will increase our knowledge regarding the occurrence of AF in
      patients with cryptogenic stroke and TIA that potentially can improve secondary prevention.
      The study will provide information on biomarkers that may be used to select cryptogenic TIA
      and stroke patients for long-term monitoring as well as information on the significance of
      short-term AF and optimal duration of cardiac rhythm monitoring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation detection rate</measure>
    <time_frame>within 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF detection rate</measure>
    <time_frame>within 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of miRNAs related to atrial fibrillation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of NT-proBNP</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Troponin-T</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of inflammation biomarkers</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prestroke/pre-TIA CHA2DS2-VASc score</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrent stroke or TIA - percentage of stroke/TIA within 12 9. Incidence of recurrent stroke or TIA - percentage of stroke/TIA</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of oral anticoagulation - percentage of patients who are using OAC drugs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiarrhythmic drugs - percentage of patients who are using antiarrhythmic drugs</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Outcome as Evaluated by an EQ-5D Questionnaire - EQ-5D quality of life score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Ischemic Stroke</condition>
  <condition>TIA</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic Reveal LINQ</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to stroke units with cryptogenic ischemic stroke or TIA
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Cryptogenic ischemic stroke patients or symptomatic TIA &lt; 21 days from symptom start.

          2. A stroke/TIA is considered to be cryptogenic if no cause can be determined despite an
             extensive workup according to the standard protocol of the participating center.
             Before inclusion to the study, the following tests are required as standard tests to
             establish the diagnosis of cryptogenic stroke or TIA:

               1. Brain MRI or CT†

               2. 12-lead ECG for AF detection

               3. 24-h ECG monitoring for AF detection and premature atrial complex analysis (e.g.
                  Holter)

               4. TEE (transesophageal echocardiography) highly recommended or TTE (transthoracic
                  echocardiography)

               5. Colour Duplex ultrasound examination of the pre-cerebral arteries

               6. CTA or MRA of head and neck to rule out other causes of stroke pathologies

          3. Age 18 to 80 at onset of TIA/stroke

          4. A participation consent form signed by the patient or a legally authorized
             representative.

               -  TIA cases with acute non-lacunar infarct on Diffusion Weighted Imaging are
                  included as TIA events.

        Exclusion Criteria:

          1. Known etiology of TIA or stroke.

          2. TIA without documented cerebral ischemia on Diffusion Weighed Imaging.

          3. Untreated hyperthyroidism

          4. Myocardial infarction less than 1 month prior to the stroke or TIA.

          5. Coronary bypass grafting less than 1 month prior to the stroke or TIA.

          6. Valvular heart disease requiring immediate surgical intervention.

          7. History of atrial fibrillation or atrial flutter.

          8. Patent Foramen Ovale (PFO) or PFO where there is or was an indication to start oral
             anticoagulation

          9. Permanent indication for OAC treatment at enrollment.

         10. Permanent contra-indication for OAC.

         11. Life expectancy less than 1 year.

         12. Pregnancy

         13. An indication for an Implantable Pulse Generator (IPG), Implantable
             Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) or an
             implantable hemodynamic monitoring system.

         14. Patient otherwise not eligible for the study or adherent for follow-up (e.g.
             non-resident) or has concurrent disease which may affect clinical outcome (e.g.
             multiple sclerosis, cancer).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Hege Aamodt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Atar, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Hege Aamodt, MD, PhD</last_name>
    <phone>+47 95867270</phone>
    <email>anhaam@ous-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Russell, MD, PhD</last_name>
    <phone>+47 23073552</phone>
    <email>david.russell@uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Østfold Hospital Trust</name>
      <address>
        <city>Kalnes</city>
        <state>Grålum</state>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ratajczak-Tretel, MD</last_name>
      <phone>+ 47 915 08 600</phone>
      <email>barbara.ratajczak@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Hege Aamodt, MD PhD</last_name>
      <phone>+4723074976</phone>
      <email>anne.hege.aamodt@ous-hf.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, Rothwell PM; Oxford Vascular Study. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol. 2015 Sep;14(9):903-913. doi: 10.1016/S1474-4422(15)00132-5. Epub 2015 Jul 27.</citation>
    <PMID>26227434</PMID>
  </reference>
  <reference>
    <citation>Tomson TT, Passman R. The Reveal LINQ insertable cardiac monitor. Expert Rev Med Devices. 2015 Jan;12(1):7-18. doi: 10.1586/17434440.2014.953059. Epub 2014 Aug 26. Review.</citation>
    <PMID>25154970</PMID>
  </reference>
  <reference>
    <citation>Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86. doi: 10.1056/NEJMoa1313600.</citation>
    <PMID>24963567</PMID>
  </reference>
  <reference>
    <citation>Ziegler PD, Rogers JD, Ferreira SW, Nichols AJ, Sarkar S, Koehler JL, Warman EN, Richards M. Real-World Experience with Insertable Cardiac Monitors to Find Atrial Fibrillation in Cryptogenic Stroke. Cerebrovasc Dis. 2015;40(3-4):175-81. doi: 10.1159/000439063. Epub 2015 Aug 28.</citation>
    <PMID>26314298</PMID>
  </reference>
  <reference>
    <citation>Christensen LM, Krieger DW, Højberg S, Pedersen OD, Karlsen FM, Jacobsen MD, Worck R, Nielsen H, Aegidius K, Jeppesen LL, Rosenbaum S, Marstrand J, Christensen H. Paroxysmal atrial fibrillation occurs often in cryptogenic ischaemic stroke. Final results from the SURPRISE study. Eur J Neurol. 2014 Jun;21(6):884-9. doi: 10.1111/ene.12400. Epub 2014 Mar 15.</citation>
    <PMID>24628954</PMID>
  </reference>
  <reference>
    <citation>Wu N, Chen X, Cai T, Wu L, Xiang Y, Zhang M, Li Y, Song Z, Zhong L. Association of inflammatory and hemostatic markers with stroke and thromboembolic events in atrial fibrillation: a systematic review and meta-analysis. Can J Cardiol. 2015 Mar;31(3):278-86. doi: 10.1016/j.cjca.2014.12.002. Epub 2014 Dec 9. Review.</citation>
    <PMID>25746020</PMID>
  </reference>
  <reference>
    <citation>Howlett PJ, Hatch FS, Alexeenko V, Jabr RI, Leatham EW, Fry CH. Diagnosing Paroxysmal Atrial Fibrillation: Are Biomarkers the Solution to This Elusive Arrhythmia? Biomed Res Int. 2015;2015:910267. doi: 10.1155/2015/910267. Epub 2015 Jul 1. Review.</citation>
    <PMID>26229966</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2016</study_first_submitted>
  <study_first_submitted_qc>October 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>February 5, 2017</last_update_submitted>
  <last_update_submitted_qc>February 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Anne Hege Aamodt</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>etiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

